Pharmacokinetics of clodronate in renal failure. 1994

H Saha, and P Castren-Kortekangas, and S Ojanen, and A Juhakoski, and J Tuominen, and O Tokola, and A Pasternack
Department of Clinical Medicine, University of Tampere, Finland.

The pharmacokinetic parameters describing the fate of one intravenous clodronate (disodium dichloromethane diphosphonate) dose was studied in 24 normal subjects and in 24 patients with different degrees of renal insufficiency. The aim of the study was to derive data for adjustment of dosage in relation to renal function. Disodium clodronate in serum and urine samples was analyzed by capillary gas chromatography with mass-selective detection. The renal clearance (CLR) of clodronate was highly dependent on renal function and declined successively with declining glomerular filtration rate (GFR). Plasma clearance (CLP) declined, too, but to a lesser degree than CLR. The impairment of renal function resulted in decreased cumulative urinary elimination of clodronate and increased total areas under the serum concentration-time curve (AUC0-infinity). Hence, as the renal elimination of clodronate diminishes with decreasing GFR, there is a related retention of the substance. As a result of the present study, the following dosages are recommended: creatinine clearance (CLCr) from 50 to 80 ml/minute, 75-100% of normal dose; CLCr 12-50 ml/minute, 50-75% of normal dose; and ClCr < 12 ml/minute, 50% of normal dose. The results must be interpreted with caution in patients with malignancy and severe skeletal disease, in whom the nonrenal clearance may vary markedly.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004002 Clodronic Acid A diphosphonate which affects calcium metabolism. It inhibits bone resorption and soft tissue calcification. Clodronate,Dichloromethylene Diphosphonate,Bonefos,Cl2MDP,Clodronate Disodium,Clodronate Sodium,Dichloromethane Diphosphonate,Dichloromethanediphosphonate,Dichloromethanediphosphonic Acid,Dichloromethylene Biphosphonate,Dichloromethylenebisphosphonate,Acid, Clodronic,Acid, Dichloromethanediphosphonic,Biphosphonate, Dichloromethylene,Diphosphonate, Dichloromethane,Diphosphonate, Dichloromethylene,Disodium, Clodronate,Sodium, Clodronate
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

H Saha, and P Castren-Kortekangas, and S Ojanen, and A Juhakoski, and J Tuominen, and O Tokola, and A Pasternack
February 2011, International journal of clinical pharmacology and therapeutics,
H Saha, and P Castren-Kortekangas, and S Ojanen, and A Juhakoski, and J Tuominen, and O Tokola, and A Pasternack
March 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
H Saha, and P Castren-Kortekangas, and S Ojanen, and A Juhakoski, and J Tuominen, and O Tokola, and A Pasternack
November 1983, Anaesthesia and intensive care,
H Saha, and P Castren-Kortekangas, and S Ojanen, and A Juhakoski, and J Tuominen, and O Tokola, and A Pasternack
January 1998, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis,
H Saha, and P Castren-Kortekangas, and S Ojanen, and A Juhakoski, and J Tuominen, and O Tokola, and A Pasternack
January 1990, Nephron,
H Saha, and P Castren-Kortekangas, and S Ojanen, and A Juhakoski, and J Tuominen, and O Tokola, and A Pasternack
February 1987, Antimicrobial agents and chemotherapy,
H Saha, and P Castren-Kortekangas, and S Ojanen, and A Juhakoski, and J Tuominen, and O Tokola, and A Pasternack
June 1987, Chemioterapia : international journal of the Mediterranean Society of Chemotherapy,
H Saha, and P Castren-Kortekangas, and S Ojanen, and A Juhakoski, and J Tuominen, and O Tokola, and A Pasternack
March 1987, Anesthesiology,
H Saha, and P Castren-Kortekangas, and S Ojanen, and A Juhakoski, and J Tuominen, and O Tokola, and A Pasternack
September 1983, British journal of clinical pharmacology,
H Saha, and P Castren-Kortekangas, and S Ojanen, and A Juhakoski, and J Tuominen, and O Tokola, and A Pasternack
January 1975, Acta pharmacologica et toxicologica,
Copied contents to your clipboard!